Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health, a major player in the Chinese pharmaceutical e-commerce market [1] - The partnership is expected to leverage JD Health's extensive user base and platform resources to promote high-quality and cost-effective medications [1] Group 2: Company Strengths - JD Health is recognized as the largest pharmaceutical e-commerce platform in China, indicating its significant market presence [1] - Zhiyun Health is noted for its leadership in chronic disease management, possessing a unique product pipeline and expertise in patient management [1]

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health, a major player in the Chinese pharmaceutical e-commerce market [1] - The partnership is expected to leverage JD Health's extensive user base and platform resources to promote high-quality and cost-effective medications [1] Group 2: Strategic Implications - This collaboration represents a strong alliance between two leading companies in their respective fields, enhancing the potential for effective promotion of health management solutions [1] - The partnership will facilitate better patient access to medications and health management services, aligning with the growing trend of digital health solutions in China [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：9955） 承董事會命 智雲健康科技集團* 有關與京東健康之服務合作協議之 自願性公告 董事長、執行董事兼首席執行官 本公告乃由智雲健康科技集團*（「本公司」，連同其子公司以及併表聯屬實體 統稱為「本集團」）自願作出。本公司董事（「董事」）會（「董事會」）欣然宣佈，本 公司近日與京東健康股份有限公司（「京東健康」，一家於香港聯交所上市的公 司，股份代號：6618.HK）訂立服務合作協議，旨在拓寬莉芙敏片®及其他P2M管 線產品的線上銷售與服務渠道，為患者提供更便捷的購藥體驗與專業的全週 期健康管理服務。 作為中國最大的醫藥電商平台，京東健康具有龐大的用戶基礎及廣泛平台資源， 而作為中國領先的慢病管理平台，本公司擁有獨特的產品管線及醫患管理專 業能力。此次雙方的合作代表強強聯合，將能高效推廣優質且具成本效益的藥 品。 – 1 – 據董事會作出一切合理查詢後所知 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 智雲健康科技集團 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09955 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | ...

证券之星消息，11月4日南向资金减持5.58万股智云健康（09955.HK）。近5个交易日中，获南向资金减 持的有5天，累计净减持99.87万股。近20个交易日中，获南向资金减持的有20天，累计净减持263.59万 股。截至目前，南向资金持有智云健康（09955.HK）5049.87万股，占公司已发行普通股的7.81%。 智云健康科技集团是一家主要从事提供医疗服务和产品的中国控股公司。该公司为医院和药店提供医疗 用品和软件即服务（SaaS）产品，为制药公司提供数字营销服务，为患者提供在线问诊和处方开具。该 公司的产品组合主要包括三大产品或服务类别。院内解决方案主要包括医院医疗用品供应、医院SaaS和 数字营销服务。药店解决方案主要包括药店用品供应和药店SaaS。个人慢病管理解决方案及其他主要包 括慢病产品、会员服务，以及保险经纪服务、广告代理服务及其他。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 202 ...

Core Insights - Southbound funds reduced their holdings in Zhiyun Health (09955.HK) by 472,600 shares on October 31, 2025, marking a decrease of 0.93% [1] - Over the past five trading days, there has been a cumulative net reduction of 1,043,100 shares, while in the last twenty trading days, the total net reduction reached 2,603,700 shares [1] - As of now, southbound funds hold 50,564,500 shares of Zhiyun Health, which accounts for 7.82% of the company's total issued ordinary shares [1] Company Overview - Zhiyun Health Technology Group is a Chinese holding company primarily engaged in providing medical services and products [2] - The company offers medical supplies and Software as a Service (SaaS) products to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescription services to patients [2] - The product portfolio includes three main categories: in-hospital solutions (medical supplies, hospital SaaS, and digital marketing), pharmacy solutions (pharmacy supplies and pharmacy SaaS), and personal chronic disease management solutions (chronic disease products, membership services, insurance brokerage services, and advertising agency services) [2]

Core Viewpoint - Southbound funds have significantly reduced their holdings in Zhiyun Health (09955.HK), indicating a potential shift in investor sentiment towards the company [1]. Group 1: Shareholding Changes - On October 21, 2025, southbound funds reduced their holdings by 399,000 shares, a decrease of 0.77% [2]. - Over the past five trading days, there have been reductions in holdings for five days, totaling a net decrease of 588,100 shares [1]. - In the last twenty trading days, southbound funds have reduced their holdings for all twenty days, with a cumulative net reduction of 1,625,000 shares [1]. Group 2: Current Holdings - As of the latest data, southbound funds hold 51,608,400 shares of Zhiyun Health, which represents 7.98% of the company's total issued ordinary shares [1]. Group 3: Company Overview - Zhiyun Health Technology Group is a Chinese holding company primarily engaged in providing medical services and products [2]. - The company's offerings include hospital medical supplies, SaaS products for hospitals, digital marketing services for pharmaceutical companies, and online consultation and prescription services for patients [2]. - The product portfolio consists of three main categories: in-hospital solutions, pharmacy solutions, and personal chronic disease management solutions [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：9955） 有關 (1) 終止須予披露交易 (2) 新須予披露交易及 (3) 戰略性業務剝離減值及一次性特定撥備 的補充公告 茲提述智雲健康科技集團*（「本公司」，連同其子公司，統稱「本集團」）日期為 2025年8月27日的公告（「該公告」），內容有關（其中包括）本集團截至2025年6月 30日止六個月（「報告期」）的未經審核中期業績、終止若干須予披露交易以及 訂立新須予披露交易。除文義另有所指外，本公告所用詞彙與該公告所界定者 具有相同涵義。 本公告旨在向本公司股東及潛在投資者提供有關(i)終止新萬格醫療股份轉讓協 議及萬迪生物科技股份轉讓協議（統稱「原始協議」）；(ii)終止江蘇成升股份轉 讓協議及訂立新出售事項補充協議的商業依據與基準；及(iii)報告期內確認的 重大減值及一次性撥備（其為呈報淨虧損的主要原因）依據的詳情。 – 1 – (1) 終止原始 ...

Core Viewpoint - Southbound funds have reduced their holdings in Zhiyun Health (09955.HK) significantly over the past trading days, indicating a bearish sentiment towards the stock [1]. Summary by Relevant Sections Southbound Fund Holdings - On October 15, southbound funds reduced their holdings by 30,100 shares, marking a decrease of 0.06% [2]. - Over the last five trading days, there has been a total net reduction of 604,100 shares [1]. - In the past 20 trading days, the cumulative net reduction reached 4,959,000 shares [1]. - Currently, southbound funds hold 52,163,700 shares of Zhiyun Health, which accounts for 8.07% of the company's total issued ordinary shares [1]. Company Overview - Zhiyun Health Technology Group is a Chinese holding company primarily engaged in providing medical services and products [2]. - The company offers medical supplies and Software as a Service (SaaS) products to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescription services to patients [2]. - The product portfolio includes three main categories: in-hospital solutions, pharmacy solutions, and personal chronic disease management solutions [2].

FF301 公司名稱: 智雲健康科技集團 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09955 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | | 100,000 | | 增加 / 減少 (-) | | | | | | USD | | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 USD | | | 100,000 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交 ...